Vivani Medical Raises $4.5M Through Equity Offering At $1.48 Per Shr

Vivani Medical, Inc. (VANI), a clinical-stage biopharmaceutical company specializing in obesity and metabolic disorder therapies, has completed a capital raise of approximately $4.5 million through a dual-track equity structure. The biotech developer offered 1.69 million common shares at $1.48 per shr in a registered direct offering, complemented by a private placement of 1.35 million shares at the same price, with Gregg Williams, the company’s Chairman of the Board, as the private placement investor. ThinkEquity served as the sole placement agent for the registered direct offering, with both tranches expected to close on January 27, 2026.

Dual Offering Structure with $4.5 Million Capital Raised

The combined equity offering represents a significant capital infusion for Vivani’s ongoing development initiatives. The registered direct offering component provided 1.69 million shares to institutional and accredited investors, while the concurrent private placement secured an additional 1.35 million shares through direct board participation. At $1.48 per shr, the pricing reflected current market dynamics for the development-stage biotech sector. The transaction structure demonstrates both institutional confidence and insider commitment to the company’s clinical pipeline advancement.

Product Pipeline: GLP-1 Therapies Driving Development Strategy

Vivani’s therapeutic focus centers on semaglutide and Exenatide-based candidates addressing the growing obesity and type 2 diabetes markets. The preclinical-stage portfolio includes NPM-139 semaglutide for obesity and chronic weight management, NPM-133 semaglutide for type 2 diabetes, and OKV-119 Exenatide for companion animal obesity (canine and feline applications). The most advanced candidate, NPM-115 Exenatide, has progressed to clinical-stage development for obesity and weight management. Notably, the company anticipates initiating human clinical development of NPM-139 in 2026, marking a significant milestone in its clinical timeline. This portfolio positions Vivani within the competitive GLP-1 therapeutic space, capitalizing on sustained market demand for obesity management solutions.

Stock Performance and Capital Deployment Plan

Over the trailing 12-month period, VANI shares traded within a range of $0.90 to $1.92, providing context for the $1.48 per shr offering price positioned near the middle of this range. The company intends to deploy the net proceeds toward accelerating research and clinical development of its product candidates, funding ongoing preclinical studies, and supporting general working capital requirements. This capital allocation strategy directly aligns with Vivani’s 2026 clinical initiation objectives, positioning the company to advance its obesity and metabolic disease therapeutic candidates through key development milestones.